Article

Delineating Drug Class and Target-Specific Adverse Events of Kinase Inhibitors

2024-08-08

Abstract excerpt

Kinase inhibitors are a successful category of therapeutics used in treating diseases such as cancer, autoimmunity, and neurodegeneration. Despite their efficacy, these drugs often present clinically relevant adverse events that can limit their therapeutic utility or lead to their failure in clinical trials. The adverse event profile of a kinase inhibitor can be explained by its off- and on-target binding profile....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 63cda6b1-8e2e-5503-b20d-3ec8b0b8a8f5
DOI: 10.1101/2024.08.07.24311573

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Delineating Drug Class and Target-Specific Adverse Events of Kinase InhibitorsDOI 10.1101/2024.08.07.24311573Read

Kinome profiling allows examination and prediction of kinase inhibitor cardiotoxicitySemantic proximity Read

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read

A Machine Learning Approach Predicts Tissue-Specific Drug Adverse EventsSemantic proximity Read

Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity Read

Selectivity filters to edit out deleterious side effects in kinase inhibitors.Semantic proximity Read

Polypharmacology is an enduring and nearly universal property of kinase inhibitorsSemantic proximity Read

Distinct Adverse Event Profiles of Eight Chemotherapeutic Agents: A FAERS Database Analysis Focusing on Peripheral NeuropathySemantic proximity Read

The kinase polypharmacology landscape of clinical PARP inhibitorsSemantic proximity Read

Associating adverse drug effects with protein targets by integrating adverse event, in vitro bioactivity, and pharmacokinetic dataSemantic proximity Read

Death by a Thousand Cuts – Combining Kinase Inhibitors for Selective Target Inhibition and Rational PolypharmacologySemantic proximity Read

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Hepatic Failure Associated with Immune Checkpoint Inhibitors: A Real-world Study from the Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseSemantic proximity Read